Looking Beyond The Deal In England
Executive Summary
Agreement of deals that promise better value for money and enhanced patient access to new treatments has become routine in England, but are they delivering?
You may also be interested in...
Novel Procurement Deal To Rid England Of Hepatitis C
NHS England has struck a “first of its kind” agreement with Gilead, AbbVie and MSD to try to eliminate hepatitis C under which the companies will seek out patients who do not yet know they have the virus.
Mixed Support For ABPI's UK Price Scheme Proposals
The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.
Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme
Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.